Insider buying last 90 days
No open-market insider purchases were filed for SOLV in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Solventum's week centered on third-quarter results that beat expectations on organic growth and earnings, with adjusted EPS of $1.45 and organic growth of approximately 4%, prompting a third guidance raise for 2026. Revenue fell 7.0% and the company reported a net loss of $12 million on $1.949 billion in total net sales, which it attributed to the reversal of advance orders and an ERP cutover rather than underlying demand. The company also disclosed it has completed over 90% of its separation from 3M, including renegotiated raw material agreements, and confirmed plans to separate its Health Information Systems business to sharpen focus on MedSurg and Dental. BTIG raised its price target to $100 from $95 while maintaining a Buy rating following the results.
Shares closed at $90.43, up 0.1% on the day, sitting above both the 50-day average of $87.71 and the 200-day average of $78.61, with one-year return at 36.4%. The GekkoIndex reading sits at 50, placing the stock in the Neutral zone, though the index has declined 12.7 over the past five sessions. Price remains 16.8% below Gekko Fair Value of $108.68.
The next earnings date falls on 25 February 2027, outside a typical 20-trading-day hold. Over the last 30 days, one unusual options signal appeared, accompanied by put premium of $342,040 and no call premium. Analyst consensus across 8 firms shows 5 buy and 3 hold ratings, with a consensus target of $94.69.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Solventum scores 3 supportive, 1 mixed and 0 headwinds across the 4 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed0 headwinds
Above 50 and 200-day
Close $89.08 is above the 50-day ($87.52) and 200-day ($78.84) averages, and the 50-day is above the 200-day.
See the chart54.5, Neutral
Reading 54.5 is in the Neutral zone.
See the GekkoIndex17.0% below
Price is 17% below Gekko Fair Value (more than 5% below).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 102 days
Next report Feb 25, 2027, 102 days away — outside a typical 20-trading-day hold.
See earningsNo data
Not enough years of history for a seasonal read.
A description of current data, not a recommendation. How this page works
Solventum closed at $89.08 on Nov 13, 2026, +20.7% over the past year, inside a 52-week range of $62.38 to $94.16.
Use the left and right arrow keys to read daily values.
Put SOLV on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Solventum works in healthcare, developing, making and selling a range of products and services aimed at meeting needs across the industry, from clinical settings to individual patients. It covers ground spanning surgical and wound care supplies through to dental products and digital health software, giving it a footprint across several distinct areas of medical and clinical support.
The company organizes its operations into four segments. Medsurg covers wound care products, I.V. site tools, sterilization systems, temperature management devices, surgical instruments, stethoscopes and electrodes. Dental Solutions supplies orthodontic and dental items including brackets, clear aligners, filling materials and bonding agents. Health Information Systems focuses on software such as physician documentation tools, billing and coding automation, classification systems, voice recognition and data visualization. Purification and Filtration provides filters, purifiers, cartridges and membranes used in purification processes.
Solventum was established in 2023 and is headquartered in Saint Paul, Minnesota. Its shares are listed on the NYSE under the ticker SOLV.
Solventum’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 54.5, in the Neutral zone, up 4 points over five sessions.
Up 4 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 41 | −0.7% | +2.1% | ||
| Accumulation | 215 | +0.3% | +0.1% | ||
| Neutral (current zone) | 348 | +0.4% | +2.0% | ||
| Distribution | 48 | +0.3% | −0.5% | ||
| Selling | 1 | Too few readings yet | |||
Average SOLV share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Solventum trades 17.0% below Gekko Fair Value of $107.31, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Solventum shares are worth, recalculated every trading day.
$107.31
Gekko Fair Value, Nov 14, 2026
17.0% Undervalued
At the end of Aug 2026 the price was 18.5% below the estimate.
No open-market insider purchases were filed for Solventum, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for SOLV in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in SOLV were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Solventum has been buying back its own shares.
From company filings.
2of the funds Gekko tracks hold SOLV.
Solventum reports on Feb 25, 2027, after the close (102 days away), and beat the EPS estimate in 7 of its last 8 reports.
Feb 25, 2027
Expected after the close, 102 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 5, 2026 | $2.55 est $1.90 | $2.21B est $2.15B | −5.7% |
| May 5, 2026 | $1.48 est $1.34 | $2.01B est $1.97B | +5.3% |
| Feb 26, 2026 | $1.57 est $1.50 | $2.00B est $1.96B | −1.2% |
| Nov 6, 2025 | $1.50 est $1.43 | $2.10B est $2.06B | +5.7% |
| Aug 7, 2025 | $1.69 est $1.45 | $2.16B est $2.12B | +1.1% |
| May 8, 2025 | $1.34 est $1.21 | $2.07B est $2.02B | +7.2% |
| Feb 27, 2025 | $1.41 est $1.50 | $2.07B est $2.05B | −5.1% |
| Nov 7, 2024 | $1.64 est $1.54 | $2.08B est $2.06B | −2.3% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Solventum is $98.38, +10.4% from the last close, from 8 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 8 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 9 | UBS | $105 | +17.9% |
| Nov 6 | Mizuho Securities | $115 | +29.1% |
| Nov 6 | BTIG | $100 | +12.3% |
| Nov 6 | Wells Fargo | $95 | +6.6% |
| Nov 6 | Piper Sandler | $110 | +23.5% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Solventum’s market cap is $15.14B, with a P/E ratio of 99.8 and revenue of $8.16B over the last twelve months.
Coverage of Solventum this week reads positive: 3 positive, 2 neutral and 2 negative headlines.
Solventum’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LHLabcorp | Neutral | 8.5% above |
| GHGuardant Health | Accumulation | 16.4% below |
| BTSGBrightSpring Health Services | Neutral | 11.0% above |
| EHCEncompass Health | Neutral | 14.7% above |
| ENSGEnsign | Neutral | 15.6% above |
| DVADaVita | Accumulation | 25.6% below |
A peer links to its own page where one exists.
Solventum’s market cap is $15.14B at the Nov 13, 2026 close of $89.08, with 170.0M shares outstanding. The shares trade on a P/E ratio of 99.8.
The consensus analyst 12-month price target for Solventum is $98.38, +10.4% from the last close. Of the 8 firms that rated the stock in the last 90 days, 5 rate it a buy, 3 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Solventum is undervalued: the Nov 13, 2026 close of $89.08 is 17.0% below Gekko Fair Value of $107.31. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Solventum is expected to report on Feb 25, 2027, after the market closes (102 days away). Analysts expect earnings of $1.77 per share on revenue of $2.09B. Solventum beat the earnings estimate in 7 of its last 8 reports, moving 4.2% on average across the report.
Solventum’s 52-week high is $94.16 and its 52-week low is $62.38; it closed at $89.08 on Nov 13, 2026, +20.7% over the past year. Over the last five years the shares peaked at $96.05 on Mar 26, 2024.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 4 items with data read as supportive (trend, fair value and earnings risk), 1 as mixed (gekkoindex). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.